Abstract:Hypopituitarism is a disease complex with variable clinical manifestations. Recent studies have improved our understanding of its pathophysiology, particularly in patients with pituitary adenomas. In that setting, hypopituitarism was previously considered a permanent and irreversible process, requiring life-long hormone replacement therapy. While this could be true in some instances, recent data demonstrated recovery of pituitary function in a large number of patients with hypopituitarism following surgical decompression. Mechanical compression of portal vessels and the pituitary stalk, by the expanding adenoma was postulated to be the predominant mechanism causing hypopituitarism in this setting. Since portal vessels also provide blood supply to the anterior lobe, ischemic necrosis of portions of the pituitary can occur as a result of increased and prolonged compression by the expanding adenoma. Recent data demonstrated increases in intrasellar pressure (ISP) in patients with pituitary macroadenomas, particularly those with hypopituitarism. The data showed that ISP measurements correlated positively with the serum prolactin levels but not with tumor sizes. It is postulated that increased ISP has predominant role in the pathogenesis of hypopituitarism in patients with pituitary adenomas while. The increase in ISP results in decreased blood flow through the portal vessels and the pituitary stalk. The latter will result in diminished delivery of hypothalamic hormones to the anterior pituitary and may also cause ischemia and/or necrosis in some portions of the normal gland. Recovery of pituitary function can thus be anticipated after surgical decompression, in patients who have viable pituitary cells.Understanding the pathophysiology of hypopituitarism and recognizing the probability for recovery of function should be emphasized in the management of patients with this disease. An important aspect of the management is patients' education about their disease, including the use of medic alert identification. The managing physician should appreciate the variable clinical manifestations of the disease and the possible occurrence of other associated neuroendocrine, neurological and neuro-ophthalmologic signs and symptoms. Treatment of hypopituitarism should not be rigid but instead, always individualized. Management should take into consideration the patients' age, sex, education, original disease process and clinical history.

Diagnosis and management of congenital hypopituitarism in children

Position statement on the diagnosis and management of congenital pituitary deficiency in adults: The French National Diagnosis and Treatment Protocol (NDTP)

Pituitary Stalk Interruption Syndrome in a 54-Year Adult Male.

Etiology, Diagnosis, and Current Management

International Guidelines for the Diagnosis and Management of Hyperinsulinism

Progress in congenital hypopituitarism

[Clinical Analysis of 13 Cases with Growth Hormone Deficiency Combined with Pituitary Stalk Interruption].

Progress, challenges and perspectives in the management of hypopituitarism

Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases

Exome Sequencing Has a High Diagnostic Rate in Sporadic Congenital Hypopituitarism and Reveals Novel Candidate Genes

Diagnosis and Management of Central Congenital Hypothyroidism

Childhood Combined Pituitary Hormone Deficiency

Pituitary imaging findings in pediatric patients with idiopathic hypogonadotropic hypogonadism

Medical Management of Hypopituitarism in Patients with Pituitary Adenomas

The molecular basis of hypoprolactinaemia

[Pituitary insufficiency: basics in diagnosis and therapy]

Hypoglycemia and Jaundice in Newborns with Pituitary Stalk Interruption Syndrome.

Diagnosis and management of pituitary adenomas in children and adolescents

Rare Case of Growth Hormone Insensitivity Syndrome Correlated With Hypothyroidism: A Case Report

Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 1, general recommendations

Age at diagnosis in patients with chronic congenital endocrine conditions: a regional cohort study from a reference center for rare diseases